AZA-S +AZA B S10
Protocols: OCI-M2 AZA-R subclones evolved from AZA-S cells after treatment with AZA doses exceeding IC50 for 8 weeks. AZA-S and AZA-R cells were incubated with 1 µM 5-azacytidine, 5 µM sulforaphane or the combination of both for 24h. Total RNA from freshly harvested cells were isolated with Trizol reagent following manufacturers protocol. 1µg of DNase I-treated RNA isolated from treated cells was used for poly-A mRNA isolation with the NEBNext Poly(A) mRNA Magnetic Isolation Module. Paired-end libraries were prepared using the NEBNext Ultra II Directional RNA Library Kit with NEBNext multiplex index oligos for Illumina (Dual Index Primers Set 1) (New England Biolabs).
ENA first public
2021-07-16
ENA last update
2021-07-16
External Id
SAMEA9334944
INSDC center alias
Biotechnology and Biomedicine Center of the Academy of Sciences and Charles University in Vestec (BIOCEV); First Faculty of Medicine; Charles University
INSDC center name
Biotechnology and Biomedicine Center of the Academy of Sciences and Charles University in Vestec (BIOCEV); First Faculty of Medicine; Charles University
INSDC first public
2021-07-16T00:14:43Z
INSDC last update
2021-07-16T00:14:43Z
INSDC status
public
Submitter Id
E-MTAB-10635:AZA-S +AZA B S10
broker name
ArrayExpress
cell line
OCI-M2
cell type
myeloblast
common name
human
developmental stage
adult
disease
acute myeloid leukemia
genotype
wild type genotype
organism part
bone marrow
sample name
E-MTAB-10635:AZA-S +AZA B S10